-
Kite licences Teneobio’s multiple myeloma targeting antibodies
pharmaceutical-technology
April 06, 2020
Gilead unit Kite has signed a licence and collaboration agreement with Teneobio for sole rights to antibodies intended for the treatment of multiple myeloma.
-
Kite’s Yescarta yields positive results in ZUMA-1 trial in refractory large B-cell lymphoma
pharmaceutical-business-review
December 11, 2019
Kite, a Gilead Company announced new data from the ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma.
-
Kite to open new manufacturing plant for cell therapies
pharmaceutical-technology
July 18, 2019
Gilead Sciences subsidiary Kite Therapeutics will build a new facility in Oceanside, California, US, to develop and manufacture viral vectors, a key material in cell therapies production.
-
Gilead Appoints CEO of Kite
contractpharma
July 15, 2019
Shaw brings extensive experience providing commercial, financial, strategic, medical and operations leadership across the biopharma industry.
-
CAR-T player Cell Medica names Kite’s European chief as CEO
fiercebiotech
August 02, 2018
Cell Medica has?appointed?Chris Nowers as its CEO. Nowers joins the company from Gilead’s Kite Pharma at a time when Cell Medica is seeking to push CAR and TCR candidates through clinical development and on to the market.
-
Kite first to submit CAR-T therapy in Europe
pharmatimes
August 02, 2017
Kite Pharma has submitted the first CAR-T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin lymphoma
-
New 3-year data supports Kite ‘cure’ hopes for CAR-T
pharmaphorum
July 24, 2017
A handful of patients with aggressive leukaemia appeared to have been cured thanks to CAR-T therapy, with some living more than four years with complete remission (CR).
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
